Friday 6 November 2026 Export GH’s income statement to Excel — free account

Guardant Health, Inc.

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue: +36.1%
EPS: −25.7%
Free cash flow: +18.7%
Total debt: +34.8%

Quarter to September 2026, against a year earlier

154.16 14.42 −8.55%

Follow GH

Alert me

Market cap: $20.6B
P/E: 0.0×
Fwd P/E: −55.6×
Dividend yield: —
F-score: 5/9
Altman Z: 2.02
Beneish M: −2.78
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Guardant Health, Inc. (GH) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023
Oncology	684 69.61%	543 73.45%	404 71.62%
Biopharma and data	210 21.40%	178 24.03%	136 24.18%
Screening	80 8.12%	5 0.69%	0 0.00%
Licensing and other	9 0.87%	13 1.82%	24 4.21%
Revenue	982	739	564

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	982 100.00%	739 100.00%	564 100.00%	450 100.00%
Revenue	982	739	564	450

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
United States	923 94.02%	697 94.34%	527 93.36%	421 93.57%	353 94.36%	265 92.30%	194 90.64%	78 85.96%	44 87.71%
International	59 5.98%	42 5.66%	37 6.64%	29 6.43%	21 5.64%	22 7.70%	20 9.36%	13 14.04%	6 12.29%
Revenue	982	739	564	450	374	287	214	91	50

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Oncology tests	Q3 FY2026	117.0K	74.0K	+58.11%
Shield screening tests	Q3 FY2026	83.0K	24.0K	+245.83%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Oncology tests	‡	‡	‡	‡	‡	‡	‡	‡
Shield screening tests	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.